A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.
Merck announced that the FDA accepted supplemental biologic license applications for the checkpoint inhibitor for early- and later-stage triple-negative breast cancer.
With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
The test detects the HER2 biomarker in breast cancer and can be completed within the same day, allowing for faster results than other HER2 testing methods.
The companies will jointly develop and commercialize DS-1062 worldwide, sharing in the development costs and the profits, but Daiichi Sankyo will maintain exclusive rights in Japan.
The multi-year collaboration will study a lung and breast cancer drug in adaptive Phase II trials, which will allow for the exploration of biomarkers of response and resistance.
